Smit Giri MD MHS
@smith__giri
Followers
447
Following
739
Media
4
Statuses
527
Medical Oncologist & Hematologist | PhD candidate @uabsoph | interested in caring for older adults with cancer
Hamden, CT
Joined December 2017
Underutilization of guideline‐rec supportive care among older adults w/ myeloma in US [Aug 5, 2019] @smith__giri et al @JournalCancer
https://t.co/2kob75W5DY
#mmsm #SuppOnc #IDonc #geriheme #cancerdisparities lower odds of influenza vaccination in 1st yr of Dx if Black & Medicaid
acsjournals.onlinelibrary.wiley.com
Among 1996 older adults in the United States who were receiving multiple myeloma–directed therapy, fewer than two-thirds received bone-modifying drugs within the first year of their diagnosis, and...
0
2
3
Geriatric assessment-identified impairments and frailty in adults with cancer younger than 65: An opportunity to optimize oncology care https://t.co/qDGDljx1g1
@mpergolottiPhD @smith__giri @GrantWilliamsMD @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert
0
19
37
Racial differences in body composition and survival among older adults with gastrointestinal malignancies https://t.co/6hLaVnFMU2
@MFowlerPhD
@smith__giri @GrantWilliamsMD @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #RacialDisparities
0
8
12
T cell exhaustion markers in multiple myeloma patients before and after physical activity intervention - Joseph et al. #ASCO23 Abstract 8060 https://t.co/4wI9A3vMyD
#mmsm #ImmunoOnc HT @rahulbanerjeeMD
2
6
18
@SuyogCancer @ASCO @OncoAlert @DrChoueiri @tompowles1 @montypal @dr_yakupergun @DrYukselUrun To help find the answer the question will need to be properly reframed: why did pembrolizumab show a signal of efficacy whereas nivolumab was inconclusive? See section 10 “Comparative and Group-specific inferences” here for the tools needed 👇
1/4 Just published our review on how to interpret RCTs focusing on key concepts such as sampling & allocation, uncertainty & variability, relevance & robustness, intention to treat & per protocol, potential outcomes & counterfactuals 👉 https://t.co/kdv7r8l52U
0
1
4
💯 Real world evidence is marketing terminology for the old “observational evidence” and implies that somehow RCTs don’t happen in the “real world”. Complete BS
@RWJE_BA @elmir1omerovic @yudapearl @AdanBecerraPhD @GreggWStone @xyu_shi @GiulioGrossi @kaulcsmc @stephensenn @drjohnm @VPrasadMDMPH RWE is a truly bullshit term. The real world simply does not provide evidence about what would have happened to a patient had they received a different treatment from the one they received, except in cases (that are almost nonexistent) where treatment choices are dictated.
3
3
25
Effect of home-based resistance training on chemotherapy relative dose intensity and tolerability in colon #cancer: The FORCE randomized control trial. https://t.co/9FjAPjOT9n
@ACS_Research @JournalCancer @DanaFarber
#ExerciseOncology #CancerResearch #SuppOnc
0
8
20
Further discussion on this topic in the #DataMethods forum here: https://t.co/kQQfgFikyA
@f2harrell @Lester_Domes
discourse.datamethods.org
Extremely helpful again. My informal take on the Ivermectin literature, having been one of the lead statisticians on two Ivermectin RCTs, is that Ivermectin has a beneficial effect that happens to be...
Appropriateness of conducting and reporting random‐effects meta‐analysis in oncology. Jinma Ren, Jia Ma, Joseph C. Cappelleri. Research Synthesis Methods.
0
3
9
👇Thoroughly enjoyed this outstanding paper @IanMarschner. Perhaps a useful interpretation of Conf(BENEFIT)=0.94 is that the region of θ values corresponding to BENEFIT has 4 or less bits of information against it as per @Lester_Domes & @dailyzad 👉
link.springer.com
BMC Medical Research Methodology - Researchers often misinterpret and misrepresent statistical outputs. This abuse has led to a large literature on modification or replacement of testing thresholds...
Confidence distributions are distributional summaries of evidence. They’re like Bayesian posteriors but without prior distribution assumptions. I wrote a tutorial paper in Statistics in Medicine for clinical trial statisticians @austrim_cre @TrialsCentre
https://t.co/sOk09yDpB3
1
2
7
Personal reflection: "Clinical prediction models & the multiverse of madness" Thanks to @BMCMedicine for 'getting this' Many reviewers/Eds pushed for writing style & tone changes This thread delves into this & why we stuck to our original vision 1/n https://t.co/djRZwLASN0
link.springer.com
BMC Medicine - Each year, thousands of clinical prediction models are developed to make predictions (e.g. estimated risk) to inform individual diagnosis and prognosis in healthcare. However, most...
7
16
71
A short 1984 chapter by Richard Peto on "The need for ignorance in cancer research" republished today https://t.co/s9hB2m9zII… foreshadows much of the progress & stagnation in cancer research over the past 40 yrs; a virtuoso piece, with a commentary here
link.springer.com
European Journal of Epidemiology - During the early 1980s both cancer biology and epidemiological methods were being transformed. In 1984 the leading cancer epidemiologist Richard Peto – who,...
1
15
49
Pleased to share our latest article on why and how drug dose-finding can be tailored to each patient’s risk-benefit trade-offs 👉 https://t.co/IXkOm0HVgx
1
10
42
@awechalekar @ash2023 Here's a link to the abstract referenced https://t.co/4DNxO8aFFz Looking forward to seeing the presentation.
0
6
11
This trial serves as an important reminder for the fact that ixazomib should have NO role in post-transplant maintenance in the current era! Adds GI toxicities without even a PFS benefit! #mmsm
Postransplant maintenance with lenalidomide and dexamethasone resulted in a 6-year PFS of 61.3%, with no benefit of adding ixazomib. https://t.co/bRwEMPJB5E
#clinicaltrialsandobservations #lymphoidneoplasia #multiplemyeloma #transplantation
5
8
31
Halv the older patients with gi cancers experience dizziness and walking impairments after chemotherapy, but it is underreported, as we never ask them! @KatrinePiper #SIOG2023 #gerionc
1
2
10
Hot off the press the new @ASCO @myESMO global curriculum recommendations for Cancer Care in Older Adults #gerionc Every oncologist should have key competencies in geriatric care! We hope this gets integrated in programs globally @HansWildiers @SIOGorg
https://t.co/zMPr2Ql4iL
2
54
123
In a couple of years we will talk about risk factor studies -- putting in a bunch of covariates in a multivariable regression model and declare the significant factors as important "risk factors" for health -- as one of the biggest mistakes in health research
28
73
414
1/⚠️Important need to knowℹ️ for using BCMA-directed agents in #MultipleMyeloma
@NoopurRajeMD and myself have u covered 👇#MedTweetorial🧵gets u what u need 🏆🆓#CME 👉🏼 https://t.co/WmGBoqEfBD Supported by edu grants from @JanssenUS & @Pfizer 📍What’s your specialty?
2
13
24
...This could be improved by: 1) improved PK/PD leading to improved exposure (AUC 2) Improved supportive care (30% of Mel200 have severe fatigue >30 days), driven by high Il-6 and low WBC (role for Siltuximab)
0
1
5